# Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

> **NCT00901927** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 14 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Mitoxantrone
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00901927
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Study was closed early due to toxicity
- **Last updated:** 2020-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00901927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00901927, "Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00901927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*